|
[1]
|
Wolfgang A, Weber. Use of PET for monitoring cancer therapy and for predicting outcome. J Nucl Med, 2005, 46(6):983-995. |
|
[2]
|
Kostakoglu L, Goldsmith SJ. 18F-FDG PET evaluation of the response to therapy for lymphoma and for breast, lung, and colorectal carcinoma. J Nucl Med, 2003, 44(2):224-239. |
|
[3]
|
Brock CS, Young H, O'Beilly SM, et al. Early evaluation of tumor metabolic response using 18F-fluorodcexyglucosc and positron emission tomography:a pilot study following the phase Ⅱ chemotherapy schedule for temozolomide in recurrent high grade gliomas. Br J Cancer, 2000, 82(3):608-615. |
|
[4]
|
Yen TD, Chang iT, Ng SH, et al. The value of 18F-FDG in the detection of stage M0 carcinoma of the nasopharynx. J Nucl Med,2005, 46(3):405-410. |
|
[5]
|
Wild D, Eyrich GK, Ciernik IF, et al. In-line (18)F-fluorodeoxyglucose positron emission tomography with computed tomography (PET/CT) in patients with carcinoma of the sinus/nasal area and orbit. J Craniomaxillofac Surg, 2006, 34(1):9-16. |
|
[6]
|
Nahas Z, Goldenberg D, Fakhry C, et al. The role of positron emission tomography/computed tomography in the management of recurrent papillary thyroid carcinoma. Laryngoscope, 2005, 115(2):237-243. |
|
[7]
|
Keidar Z, Haim N, Guralnik L, et al. PET-CT using 18F-FDG in suspected lung eaneer recurrence:diagnostic value and impact on patient management. J Nucl Med, 2004, 45(10):1640-1646. |
|
[8]
|
Weber WA, Peterson V, Schmidt B, et al. Positron emission tomography in non-small-cell lung cancer:prediction of response to chemotherapy by quantitative assessment of glucose use. J Clin Oncol, 2003, 21(14):2651-2657. |
|
[9]
|
Pottgen C, Levegrun S, Theegarten D, et al. Value of 18F-fluoro-2-deoxy-D-glucose-positron emission tomography/computed tomography in non-small-cell lung cancer for prediction of pathologic response and times to relapse after neoadjuvant chemoradiotherapy. Clin Cancer Res, 2006, 12(1):97-106. |
|
[10]
|
Smith IC, Welch AE, Hutcheon AW, et al. Positron emission tomography using 18F-fluorodeoxy-D-glucose to predict the pathologic response of breast cancer to primary chemotherapy. J Clin Oncol, 2000, 18(8):1676-1688. |
|
[11]
|
Biersaek HJ, Bender H, Palmedo H, et al. FDG-PET in monitoring therapy of breast cancer. Eur J Nuel Med Imaging, 2004, 31(Suppl 1):S112-S117. |
|
[12]
|
Biersaek HJ, Palmedo H. Locally advanced breast cancer:is PET useful for monitoring primary chemotherapy?. J Nucl Med, 2003,44(11):1815-1817. |
|
[13]
|
Peter L, Isabel Igerc, Thomas Beyer, et al. Advantages and limitations of FDG PET in the follow-up of breast cancer. Eur J Nucl Med Mol Imaging, 2004, 31(Suppl 1):S129-S134. |
|
[14]
|
Pelosi E, Messa C, Picchio M, et al. Value of integrated PET/CT for lesion localization in cancer patients:a comparative study. Eur J Nucl Med Med Imaging, 2004, 31(7):932-939. |
|
[15]
|
Elinor Goshen, Tima Davidson, S.Tzila Zwas, et al. PET/CT in the evaluation of response to treatment of liver metastases from colorectal cancer with bevacizumab and irinotecan. Technol Cancer Res Treat, 2006, 5(1):37-43. |
|
[16]
|
Wieder HA, Beer A J, Lordick F, et al. Comparison of changes in tumor metabolic activity and tumor size during chemotherapy of adenocarcinomas of the esophagoostric junction. J Nucl Med,2005, 46(12):2029-2034. |
|
[17]
|
Freudenberg IS, Antoch G, Schutt P, et al. FDG PET-CT in restaging of patients with lymphoma. Eur J Nucl Meal Mol Imaging,2004, 31(3):325-329. |
|
[18]
|
Meignan M, Haioun C, Itti E, et al. Value of[18F] fluorodeoxy-glucose-positron emission tomography in managing patients with aggressive non-Hodgkin's lymphoma. Clin Lymphoma Mveloma, 2006,6(4):306-313. |
点击查看大图
下载: